Target validation in silico
| Autor: | Ton Rullmann, Wynand Alkema, Andrea van Elsas |
|---|---|
| Přispěvatelé: | Data Sciences for Life Science & Health |
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: |
drug design
In silico Clinical Biochemistry pharmaceutical/methods Computational biology Bioinformatics Drug Delivery Systems drug delivery systems/methods Virtual patient Drug Discovery computer simulation Technology Pharmaceutical Medicine humans Pharmacology Protein function technology pharmaceutical/methods business.industry phenotypes biotechnologie Phenotype technology Molecular Medicine reproducibility of results Biosimulation business |
| Zdroj: | Expert Opinion on Therapeutic Targets, 10(5), 635-638. Ashley |
| ISSN: | 1472-8222 |
| DOI: | 10.1517/14728222.10.5.635 |
| Popis: | Genomics has multiplied the number of targets for new therapeutic interventions, but this has not yet lead to a marked increase of pharma pipeline outputs. The complexity of protein function in higher order biological systems is often underestimated. Translation from in vitro and in vivo results to the human setting frequently fails due to unforeseen toxicity and efficacy issues. Biosimulation addresses these issues by capturing the complex dynamics of interacting molecules and cells in mechanistic, predictive models. A central concept is that of the virtual patient, an encapsulation of a specific pathophysiological behaviour in a biosimulation model. The authors describe how virtual patients are being used in target identification, target validation and clinical development, and discuss challenges for the acceptance of biosimulation methods. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|